GATA3 and mature T-cell and NK-cell non-Hodgkin lymphoma: Given the high CCR4 expression observed in VAV1-mutant tumors and the positive correlation between CCR4 and GATA3 expression in human PTCL-GATA3 [49], PTCL with VAV1 mutations should be evaluated for CCR4 expression as mogamulizumab could be a treatment option [43].